Novel bone antiresorptive approaches.
Inhibition of bone resorption is a mechanism that has been clinically validated as a means to control bone loss in diseases such as postmenopausal osteoporosis. The development of marketable drugs in this area has resulted in significant clinical benefits; however, improvements can still be made. Several novel antiresorptive mechanisms are currently under consideration in the pharmaceutical industry, which will hopefully result in the development of improved bone antiresorptive therapies.
Lark
Michael W
MW
Department of Musculoskeletal Diseases Biology, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA. michael_lark-1@gsk.com
James
Ian E
IE
D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans
D004164:Diphosphonates